UK Cell And Gene Therapy Clinical Trials Market Size & Outlook
UK cell and gene therapy clinical trials market, 2018-2030 (US$M)
Related Markets
UK cell and gene therapy clinical trials market highlights
- The UK cell and gene therapy clinical trials market generated a revenue of USD 535.1 million in 2023 and is expected to reach USD 1,428.3 million by 2030.
- The UK market is expected to grow at a CAGR of 15.1% from 2024 to 2030.
- In terms of segment, phase ii was the largest revenue generating phase in 2023.
- Phase III is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy clinical trials market data book summary
| Market revenue in 2023 | USD 535.1 million |
| Market revenue in 2030 | USD 1,428.3 million |
| Growth rate | 15.1% (CAGR from 2023 to 2030) |
| Largest segment | Phase ii |
| Fastest growing segment | Phase III |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
Other key industry trends
- In terms of revenue, UK accounted for 5.7% of the global cell and gene therapy clinical trials market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK cell and gene therapy clinical trials market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,428.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy Clinical Trials Market Scope
Cell And Gene Therapy Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK cell and gene therapy clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 49.92% in 2023. Horizon Databook has segmented the UK cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
The UK market is lucrative owing to tax credits and various expansions in developed countries. For instance, in the UK, there are two tax credits for large companies and small and medium-sized companies. The large companies can claim 30% deductible from the income of their R&D expenditure. In case of small & medium-sized enterprises, it is 25% for R&D expenditure. The UK’s success in the early science has built on attracting investment & research activity form global pharmaceutical companies to famous universities & research centers in the UK.
The UK government has already committed to increase 2.4% of GDP share spent on R&D by 2027 and 3% by 2030. The NHS has huge potential for driving global investments, with UK’s health service offering significant opportunities to clinical trials for novel vaccines and medicines with expertise and access to health data.
As per Association of the British Pharmaceutical Industry (ABPI), in 2018, the Medicines and Healthcare Products Regulatory Agency (MHRA) got 955 requests for Clinical Trial Authorizations (CTA) out of which 708 applications were for phase 2/3, 136 were for phase 1, and 111 for phase 4. Around 798 of those were commercial and 157 non-commercial, presenting the noteworthy role that pharmaceutical firms have in driving UK clinical research.
Reasons to subscribe to UK cell and gene therapy clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK cell and gene therapy clinical trials market databook
-
Our clientele includes a mix of cell and gene therapy clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UK cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK cell and gene therapy clinical trials market size, by phase, 2018-2030 (US$M)
UK Cell And Gene Therapy Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
